Excellence in innovation | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's commitment to innovation in pharmaceutical production, delivering cutting-edge solutions for your biopharmaceutical needs.
Search
Expertise in microbial | Bioxcellence | Boehringer Ingelheim
Leverage BioXcellence's expertise in microbial production, providing high-quality, reliable biopharmaceutical manufacturing solutions for your business.
Vietnam
Vietnam Boehringer Ingelheim Vietnam in an overview: Learn more about locations.
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Every Drop Counts – Water Stewardship at Boehringer Ingelheim
How we work actively to protect clean water and reduce our water footprint in all communities where we operate
Our Biotech Story | Bioxcellence | Boehringer Ingelheim
Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim
Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
MORE GREEN: Reducing emissions throughout the supply chain
How Thermo Fisher is contributing to the decarbonization of Boehringer Ingelheim’s supply chain by reducing their own emissions
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
European Commission decision for Pradaxa® in children with VTE
Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age
Solid Fundations | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
Living Independence
Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
Boehringer Ingelheim: Discover the app set to transform animal care in rural India
Learn about the app set to transform animal care in rural India. Women will be empowered and goat welfare will be promoted. From idea to app!
Purpose: Finding the long-missed meaning
Cancer survivor Missy Pappion is happy at Boehringer Ingelheim after climbing the corporate ladder
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
Interview Dr Mehdi Shahidi
Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
Global language learning platform for our people
One global learning platform for languages, countless opportunities to grow your career
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Upstream and Downstream Processing | Bioxcellence | Boehringer Ingelheim
Experience our exceptional expertise in upstream & downstream biopharmaceutical processing, utilizing mammalian cell cultures & microbial organisms.
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide